Cullinan To Search For Oncology’s Diamonds In The Rough

 
• By Joseph Haas

With a business model based on portfolio management, the new company backed by MPM Capital plans to de-risk novel cancer therapies for out-licensing upon proof-of-concept or other value-creating inflection points.

Owen Hughes, CEO of Cullinan Oncology, and Patrick Bauerle, chief scientific officer of Cullinan
Cullinan CEO Owen Hughes, CSO Biologics Patrick Bauerle • Source: Source: Cullinan Oncology LLC

More from Financing

More from Business